Tag
Alzheimer’s
-
Another Alzheimer’s treatment takes a different route than the rest
Editor’s Note: This is part 2 of a two-part package on the pipeline for Alzheimer’s disease drugs. Check out part…
-
Aside from Eli Lilly’s drug, what else is in the Alzheimer’s pipeline?
Eli Lilly recently announced that the FDA had granted a breakthrough therapy designation for donanemab, its investigational antibody therapy for…
-
New Alzheimer’s drug draws attention from federal, independent groups
Liz Seegert, AHCJ’s topic leader on aging, contributed to this article. Federal policy experts and the influential Institute for Clinical…
-
Alzheimer’s drug approved Monday by FDA raises questions for journalists
Part two of two parts; the first ran Thursday, June 10. There’s still a great deal we don’t yet understand…
-
FDA approves new Alzheimer’s drug, but controversy persists
Part one of two parts; the second runs tomorrow, Friday, June 11. You might think that the first new drug…
-
New Alzheimer’s drug shows promise, but don’t celebrate yet
A recent announcement by drugmaker Eli Lilly that its drug donanemab slowed the progression of Alzheimer’s by nearly one-third is…
-
Long-term effects of COVID-19 on the brain could mean a wave of dementia cases
We don’t yet know the severity of COVID-19’s long-term effects on the brain, but a group of international researchers is…
-
Biogen submits BLA for an Alzheimer’s drug with a controversial past
Could an Alzheimer’s drug finally be on the horizon? Possibly ― if the FDA agrees with data from several Biogen…
-
How one reporter leveraged a conference opportunity to report dementia series
How do you wrap your arms around a topic as big as dementia to create a five-part series that’s cohesive,…
-
Are the eyes a window into Alzheimer’s risk?
Can your eyes predict the onset of Alzheimer’s disease (AD) years before cognitive symptoms appear? Findings in a recent study…